First of all the candidates need to register themselves on the login portal after that they can complete their form-filling process on the GATE Online Application Processing System (GOAPS).

Actuate Therapeutics (ACTU) has filed for up to 2,777,778 share offering by selling stockholders.

Elraglusib is a Class-LeadingGSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer Trials Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Actuate Therapeutics has won Food and Drug Administration orphan-drug designation for its lead investigational drug product in a group of rare cancerous tumors. Actuate on Wednesday said the ...

LOYALTYPOINT INC, ACTUATE CORP, and PORTAL SOFTWARE INC. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio ...

11, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of ...

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma.

CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug ...